Effect of transarterial infusion therapy using carboplatin for hepatocelluar carcinoma with macroscopic vascular invasion

Effect of transarterial infusion therapy using carboplatin for hepatocelluar carcinoma with macroscopic vascular invasion - Effect of transarterial infusion therapy using carboplatin for hepatocelluar carcinoma with macroscopic vascular invasion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016041

Enrollment

Registered

2014-12-24

Start date

2014-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocelluar carcinoma

Interventions

transarterial infusion therapy using carboplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Resectable hepatocelluar carcinoma with macroscopic vascular invasion 2)Child-Pugh classification A 3)PS(ECOG) score:0-1 4)Documently informed consented

Exclusion criteria

Exclusion criteria: 1)Case with Extrahepatic metastasis 2)Case with complication as below(excluded chronic hepatitis and chirrosis) (1)Uncontrollable Cardiac dysfunction (2)AMI onset within 6 months (3)Renal failure (4)Active infection(excluded viral hepatitis) (5)Active GI bleeding (6)Active double cancer (7)Hepatic coma and mentalillness 3)Pregnantwoman,nursewoman and possible pregnantwoman 4)Case that are not suitable and not listed above

Design outcomes

Primary

Measure	Time frame
Desease free survival	—

Secondary

Measure	Time frame
respons rate of transarterial infusion therapy using CAM(carboplatin, adoriamaicin, mitomycin C), Over all survival, safty	—

Countries

Japan

Contacts

Public ContactYoshinao Tanahashi

Fujita Health University School of Medicine Depertment of hepatobiriary and transplant surgery

yoshinao@fujita-hu.ac.jp0562-93-9248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026